NFKB1 and diabetic kidney disease: In an in vivo study, Pal and colleagues demonstrated that mangiferin suppressed inflammatory lesion in diabetic nephropathy by reducing TNF-α and IL-6 levels along with reduced expression of IKK and subsequent inhibition of NF-κB pathway activation40.